A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 18182-18203
DOI: 10.1021/acs.jmedchem.6c00521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 31.07.2026. Verfasst von Chao Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan430071, China. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Drug Resistance, Neoplasm, Antineoplastic Agents. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China (NSFC), Hubei Research Center of Fundamental Science-Chemistry.
Abstract (Originalsprache)
Estrogen receptor α (ERα) remains a pivotal therapeutic target for ER-positive (ER+) breast cancer, yet resistance to endocrine therapies driven by ligand-binding pocket (LBP) mutations demands novel strategies. To integrate the complementary strengths of binding modalities of the orthosteric LBP and the allosteric coactivator binding site (CBS) against endocrine resistance, we designed a series of ERα LBP/CBS dual-targeting proteolysis-targeting chimeras (PROTACs). The lead compound P5 demonstrated high binding affinities for LBP and CBS sites, potent antiproliferative activity, and efficient ERα degradation efficacy across a panel of breast cancer cell lines via the ubiquitin-proteasome system. Mechanistically, P5 triggered S-phase cell cycle arrest and apoptosis in LCC2 cells. In vivo, P5 exhibited significant tumor growth inhibition in the LCC2 xenograft model, with efficacy comparable to fulvestrant, and a favorable safety profile. Our findings validate the LBP/CBS dual-targeting PROTAC strategy as a promising avenue for overcoming resistance in ER+ breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan430071, China.
- Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan University, Wuhan430060, China.
- Frontier Science Center for Immunology and Metabolism, State Key Laboratory of Virology and Biosafety, Provincial Key Laboratory of Developmentally Originated Disease, Key Laboratory of Combinatorial Biosynthesis and Dr…
ORCID-Profile: Lilan Xin, Hai-Bing Zhou
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China (NSFC)
- Hubei Research Center of Fundamental Science-Chemistry
Zitieren
APA
Wang, C., Xu, B., Xin, L., Guo, Z., Deng, X., Dong, C., Yang, J., & Zhou, H. B. (2026). A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α. Journal of Medicinal Chemistry, 69(15), 18182-18203. https://doi.org/10.1021/acs.jmedchem.6c00521
Vancouver
Wang C, Xu B, Xin L, Guo Z, Deng X, Dong C, et al. A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α. Journal of Medicinal Chemistry. 2026;69(15):18182-18203. doi:10.1021/acs.jmedchem.6c00521
BibTeX
@article{Wang2026,
author = {Wang, Chao and Xu, Bin and Xin, Lilan and Guo, Zhangxiao and Deng, Xiaofei and Dong, Chune and Yang, Jian and Zhou, Hai-Bing},
title = {A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {18182--18203},
doi = {10.1021/acs.jmedchem.6c00521}
}
EUVIMED